SAWAI GROUP HOLDINGS Co., Ltd. Logo

SAWAI GROUP HOLDINGS Co., Ltd.

A leading Japanese generic drug maker expanding into digital health and wellness solutions.

4887 | T

Overview

Corporate Details

ISIN(s):
JP3323040000
LEI:
Country:
Japan
Address:
大阪市淀川区宮原5丁目2−30
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sawai Group Holdings Co., Ltd. is a holding company primarily engaged in the pharmaceutical business. Its core subsidiary, Sawai Pharmaceutical Co., Ltd., is a leading Japanese manufacturer of generic drugs, focusing on the research, development, production, and sale of high-quality, affordable medications across various therapeutic areas, including treatments for hypertension and dyslipidemia. The Group aims to contribute to reducing patient financial burdens and supporting sustainable healthcare systems. In addition to its core generics business, the company is expanding into the broader healthcare field, including digital health solutions and wellness services through subsidiaries such as FrontAct, which develops treatment support apps and provides health monitoring devices. The Group's mission is to support healthier lives for people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 03:04
Registration Form
訂正発行登録書
Japanese 24.2 KB
2025-06-27 02:47
Regulatory News Service
訂正発行登録書
Japanese 10.0 KB
2025-06-26 07:49
Post-Annual General Meeting Information
臨時報告書
Japanese 31.2 KB
2025-06-24 08:06
Governance Information
内部統制報告書-第4期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-24 08:06
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 08:05
Annual Report
有価証券報告書-第4期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2025-05-27 05:40
Registration Form
訂正発行登録書
Japanese 9.6 KB
2025-05-27 02:50
Regulatory News Service
臨時報告書
Japanese 20.1 KB
2025-04-03 06:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.4 KB
2025-03-05 07:02
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-02-05 07:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2025-01-08 07:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.7 KB
2024-12-04 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.5 KB
2024-11-11 07:47
Interim Report
確認書
Japanese 9.1 KB
2024-11-11 07:46
Interim Report
半期報告書-第4期(2024/04/01-2025/03/31)
Japanese 350.6 KB

Automate Your Workflow. Get a real-time feed of all SAWAI GROUP HOLDINGS Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SAWAI GROUP HOLDINGS Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SAWAI GROUP HOLDINGS Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS
MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America
MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America
MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America
MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea
140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea
432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America
MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America
MDXG
Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America
MNMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.